Matinas BioPharma Holdings (MTNB) Capital Expenditures (2013 - 2023)
Matinas BioPharma Holdings (MTNB) posted quarterly Capital Expenditures of $16000.0 for Q3 2023, down 93.6% year-over-year from $250000.0 in Q3 2022, and down 61.9% quarter-over-quarter from $42000.0 in Q4 2022.
Matinas BioPharma Holdings (MTNB) Capital Expenditures (2013 - 2023) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Capital Expenditures for 10 consecutive years, with $16000.0 the latest figure, recorded in Q3 2023.
- In Q3 2023, Capital Expenditures fell 93.6% year-over-year to $16000.0; the TTM figure through Dec 2023 stood at $308000.0 (down 65.47% YoY), while the FY2023 annual figure was $218000.0, down 75.56% from the prior year.
- Capital Expenditures retreated to $16000.0 in Q3 2023 per MTNB's latest filing, from $42000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $545000.0 in Q1 2022 and bottomed at $5749.0 in Q1 2020.
- Historically, Capital Expenditures has averaged $135516.5 across 5 years, with a median of $48500.0 in 2022.
- Annual changes were most pronounced in 2019 — Capital Expenditures jumped 100.35% — and 2023, when it slumped 93.6%.
- Matinas BioPharma Holdings' Capital Expenditures stood at $73430.0 in 2019, then tumbled by 92.17% to $5749.0 in 2020, then jumped by 522.93% to $35812.0 in 2021, then increased by 17.28% to $42000.0 in 2022, then plunged by 61.9% to $16000.0 in 2023.
- Business Quant data shows MTNB's Capital Expenditures at $16000.0 in Q3 2023, $42000.0 in Q4 2022, and $250000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 16,000.00 |
| Sep 30, 2023 | 16,000.00 |
| Dec 31, 2022 | 42,000.00 |
| Dec 31, 2022 | 42,000.00 |
| Sep 30, 2022 | 250,000.00 |
| Sep 30, 2022 | 250,000.00 |
| Jun 30, 2022 | 55,000.00 |
| Jun 30, 2022 | 55,000.00 |
| Mar 31, 2022 | 545,000.00 |
| Mar 31, 2022 | 545,000.00 |
| Dec 31, 2021 | 35,812.00 |
| Dec 31, 2021 | 35,812.00 |
| Mar 31, 2020 | 5,749.00 |
| Mar 31, 2020 | 5,749.00 |
| Sep 30, 2019 | 73,430.00 |
| Sep 30, 2019 | 73,430.00 |
| Jun 30, 2019 | 317,928.00 |
| Jun 30, 2019 | 317,928.00 |
| Mar 31, 2019 | 14,246.00 |
| Mar 31, 2019 | 14,246.00 |